



March 17, 2026

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

**Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

Encl.: a/a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

info@lupin.com | www.lupin.com

Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India

- Lupin will market the product under the brand names Semanext[®] and Lupin's Livarise[®]
- Zydus will market the product under the brand names SEMAGLYN[™], MASHEMA[™] and ALTERME[™]
- Partnership aims to strengthen patient access for advanced diabetes and weight management therapies

Mumbai, India, March 17, 2026: Global pharma major Lupin Limited (Lupin) has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited (Zydus), an innovation-led life-sciences company, to expand access to innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in India. This partnership brings together Lupin's extensive reach in the Indian market and Zydus' robust development capabilities, driven by the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in India under the brand names Semanext[®] and Lupin's Livarise[®]. Zydus will continue to market the product under the brand names SEMAGLYN[™], MASHEMA[™] and ALTERME[™]. As part of the agreement, Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.

Nilesh Gupta, Managing Director, Lupin, said, "Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India."

Speaking on the development, **Managing Director, Zydus Lifesciences Ltd., Dr. Sharvil Patel** said, "Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients' needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India."

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

- as monotherapy, when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes

It is also indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

About Zydus Lifesciences Limited

Zydus Lifesciences Limited is an innovation-led global life sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a strong international presence across the United States, India, and other global markets. As of September 30, 2025, the group employs approximately 29,000 people worldwide, including 1,500 scientists engaged in research and development. The company is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

For more details, please visit: www.zyduslife.com

For further information or queries, please contact:

Lupin

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin

Email: rajalakshmiazariah@lupin.com

Zydus

Sujatha Rajesh

Email: sujatha.rajesh@zyduslife.com

Mobile: 9974051180